Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Voyager Therapeutics, Inc. Common Stock (VYGR)

Biological Products, (no Disgnostic Substances)

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

75 HAYDEN AVENUE
LEXINGTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/11/2015

Market Cap

351,739,785

Shares Outstanding

46,150,000

Weighted SO

53,924,392

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

DAWN --.--%

XFOR --.--%

INZY --.--%

ABOS --.--%

MREO --.--%

TERN --.--%

HOOK --.--%

LPTX --.--%

PRQR --.--%

Beta

0.9630

Last Div

0.0000

Range

6.06-11.72

Chg

-0.0400

Avg Vol

430145

Mkt Cap

351739785

Exch

NASDAQ

Country

US

Phone

857 259 5340

DCF Diff

0.5325

DCF

8.4775

Div Yield

0.0000

P/S

2.4466

EV Multiple

-180.8037

P/FV

1.1100

Div Yield %

0.0000

P/E

41.2619

PEG

1.7350

Payout

0.0000

Current Ratio

9.5083

Quick Ratio

9.5083

Cash Ratio

1.8970

DSO

8.2536

DIO

0.0000

Op Cycle

8.2536

DPO

195.3215

CCC

-187.0679

Gross Margin

0.9661

Op Margin

-0.0463

Pretax Margin

0.0675

Net Margin

0.0628

Eff Tax Rate

0.0704

ROA

0.0207

ROE

0.0331

ROCE

-0.0168

NI/EBT

0.9296

EBT/EBIT

-1.4591

EBIT/Rev

-0.0463

Debt Ratio

0.0154

D/E

0.0201

LT Debt/Cap

0.0000

Total Debt/Cap

0.0197

Int Coverage

0.0000

CF/Debt

-2.9284

Equity Multi

1.3005

Rec Turnover

44.2230

Pay Turnover

1.8687

Inv Turnover

0.0000

FA Turnover

2.7765

Asset Turnover

0.3296

OCF/Share

-0.3417

FCF/Share

-0.4222

Cash/Share

6.4277

OCF/Sales

-0.1372

FCF/OCF

1.2355

CF Coverage

-2.9284

ST Coverage

-2.9284

CapEx Coverage

-4.2467

Div&CapEx Cov

-4.2467

P/BV

1.1100

P/B

1.1100

P/S

2.4466

P/E

41.2619

P/FCF

-14.4327

P/OCF

-18.8739

P/CF

-18.8739

PEG

1.7350

P/S

2.4466

EV Multiple

-180.8037

P/FV

1.1100

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering GlobeNewswire Inc. Jan 04, 22:45 Voyager Therapeutics Announces Pricing of Public Offering Benzinga Jan 04, 17:08 Voyager Therapeutics Stock Tanked After-Hours - Here's Why MarketWatch Jan 02, 15:53 Why investors should be wary of New Year 'head fakes' for this hot asset class MarketWatch Jan 02, 09:24 Why investors should be wary of New Year 'head fakes' for this hot asset class MarketWatch Jan 02, 08:18 Why investors should be wary of New Year 'head fakes' for this hot asset class

Revenue Product Segmentation